Minerva Neuroscience
Clinical development of treatments for central nervous system disorders.
Launch date
Employees
Market cap
AUD31.9m
Enterprise valuation
(AUD16m) (Public information from Sep 2024)
Share price
$2.817 NERV
Waltham Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 41.2m | - | - | - | 20.0m | - | 19.8m |
| EBITDA | 1.9m | (45.3m) | (25.2m) | (23.1m) | - | - | - |
| % EBITDA margin | 5 % | - | - | - | - | - | - |
| Profit | 1.9m | (49.9m) | (32.1m) | (30.0m) | (12.9m) | (29.5m) | (28.7m) |
| % profit margin | 5 % | - | - | - | (65 %) | - | (145 %) |
| EV / revenue | 2.4x | - | - | - | 1.0x | - | 1.0x |
| EV / EBITDA | 51.8x | -0.8x | -0.3x | -1.9x | - | - | - |
| R&D budget | 22.0m | 32.0m | 14.6m | 12.7m | - | - | - |
| R&D % of revenue | 54 % | - | - | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
$15.0m | Debt | ||
$31.0m | Post IPO Equity | ||
| N/A | $1.0m | Post IPO Equity | |
$4.2m | Post IPO Equity | ||
$90.0k | Post IPO Equity | ||
| Total Funding | - | ||
Related Content
Recent News about Minerva Neuroscience
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.